Katrin Mestermann

652 total citations · 1 hit paper
11 papers, 493 citations indexed

About

Katrin Mestermann is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Katrin Mestermann has authored 11 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Katrin Mestermann's work include CAR-T cell therapy research (11 papers), Virus-based gene therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Katrin Mestermann is often cited by papers focused on CAR-T cell therapy research (11 papers), Virus-based gene therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Katrin Mestermann collaborates with scholars based in Germany, Spain and United States. Katrin Mestermann's co-authors include Michael Hudecek, Hermann Einsele, Silke Frenz, Thomas Nerreter, Justus Weber, Theodoros Giavridis, Michel Sadelain, Julian Rydzek, Andreas Mades and María‐Belén Vídriales and has published in prestigious journals such as Blood, Oncogene and Science Translational Medicine.

In The Last Decade

Katrin Mestermann

10 papers receiving 491 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

2019 379 citations Katrin Mestermann, Theodoros Giavridis et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katrin Mestermann Germany	4	430	178	161	149	139	11	493
Andreas Mades Germany	5	430 1.0×	181 1.0×	180 1.1×	140 0.9×	157 1.1×	6	516
Silke Frenz Germany	4	459 1.1×	187 1.1×	180 1.1×	163 1.1×	147 1.1×	6	531
Michael C. Kann United States	9	484 1.1×	182 1.0×	231 1.4×	202 1.4×	162 1.2×	17	625
Mohamed-Reda Benmebarek Germany	9	594 1.4×	190 1.1×	213 1.3×	259 1.7×	148 1.1×	17	686
Martina Schüßler‐Lenz Germany	6	349 0.8×	103 0.6×	180 1.1×	127 0.9×	119 0.9×	9	445
Eugenia Zah United States	4	659 1.5×	269 1.5×	231 1.4×	211 1.4×	176 1.3×	5	700
John Lattin United States	5	648 1.5×	213 1.2×	256 1.6×	294 2.0×	162 1.2×	8	742
Jolanta Stefanski United States	7	353 0.8×	100 0.6×	156 1.0×	164 1.1×	140 1.0×	12	403
Dylan J. Drakes United States	4	606 1.4×	220 1.2×	236 1.5×	289 1.9×	161 1.2×	5	711
Danielle Vanasse United States	6	507 1.2×	158 0.9×	189 1.2×	135 0.9×	142 1.0×	7	549

Countries citing papers authored by Katrin Mestermann

Since Specialization

Citations

This map shows the geographic impact of Katrin Mestermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrin Mestermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrin Mestermann more than expected).

Fields of papers citing papers by Katrin Mestermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrin Mestermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrin Mestermann. The network helps show where Katrin Mestermann may publish in the future.

Co-authorship network of co-authors of Katrin Mestermann

This figure shows the co-authorship network connecting the top 25 collaborators of Katrin Mestermann. A scholar is included among the top collaborators of Katrin Mestermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrin Mestermann. Katrin Mestermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Schultz, Ursula, Manuel Effenberger, Stephen Goldrick, et al.. (2025). Impact of Serum/Xeno‐Free Medium and Cytokine Supplementation on CAR‐T Cell Therapy Manufacturing in Stirred Tank Bioreactors. Biotechnology Journal. 20(9). e70114–e70114. 1 indexed citations

2.

Egri, Péter, Carmen Sanges, Sophia Danhof, et al.. (2024). Reinforcement Learning Based Resource Management for CAR T-Cell Therapies. Procedia CIRP. 125. 154–159. 1 indexed citations

3.

Mestermann, Katrin, Andoni Garitano-Trojaola, & Michael Hudecek. (2024). Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors. BioDrugs. 39(1). 33–51. 2 indexed citations

4.

Peng, Haiyong, et al.. (2022). ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 41(34). 4104–4114. 22 indexed citations

5.

Prommersberger, Sabrina, Razieh Monjezi, Lacramioara Botezatu, et al.. (2022). Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer. Methods in molecular biology. 2521. 41–66. 3 indexed citations

6.

Frenz, Silke, María‐Belén Vídriales, Marcos González, et al.. (2021). Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 138(19). 1830–1842. 74 indexed citations

7.

Mestermann, Katrin, Markus Machwirth, Ulrike Köhl, et al.. (2020). P09.08 Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol. A55.2–A56.

8.

Arcangeli, Silvia, Katrin Mestermann, Justus Weber, et al.. (2020). Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology. 32(5). 398–407. 9 indexed citations

9.

Mestermann, Katrin, Theodoros Giavridis, Justus Weber, et al.. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine. 11(499). 379 indexed citations breakdown →

10.

Mestermann, Katrin, et al.. (2019). Abstract A037: A novel pharmacologic “ON/OFF” switch to modulate CAR-T-cell function in vitro and in vivo. Cancer Immunology Research. 7(2_Supplement). A037–A037. 1 indexed citations

11.

Mestermann, Katrin, Julian Rydzek, Silke Frenz, et al.. (2018). A Novel Pharmacologic 'Remote Control' to Steer CAR-T Cell Function In Vivo. Blood. 132(Supplement 1). 2055–2055. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact